18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: Implications for future clinical trials

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 3, 2012, Pages 521-528

  Win, Thida ^a   Lambrou, Tryphon ^b   Hutton, Brian F ^b   Kayani, Irfan ^b   Screaton, Nicholas J ^c   Porter, Joanna C ^d   Maher, Toby M ^e   Endozo, Raymondo ^b   Shortman, Robert I ^b   Lukey, Pauline ^f   Groves, Ashley M ^b  

^a LISTER HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Computed tomography; Interstitial; Lung diseases; Metabolism; Positron emission tomography; Reproducibility

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOGRAM; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG INTERSTITIUM; MALE; POSITRON EMISSION TOMOGRAPHY; CLINICAL TRIAL; FIBROSING ALVEOLITIS; LUNG; METABOLISM; METHODOLOGY; REPRODUCIBILITY; SCINTISCANNING; TIME;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84859640369     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1986-7     Document Type: Article

References (35)

1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810-6. (Pubitemid 44511663)
2. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517-25. (Pubitemid 32758505)
3. Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest. 2007;132:637-50. (Pubitemid 47282399)
4. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.
5. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 2007;8:822-30.
6. Jeon TY, Lee KS, Yi CA, Chung MP, Kwon OJ, Kim BT, et al. Incremental value of PET/CT Over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2010;195:370-6.
7. Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG-PET/CT. J Nucl Med. 2009;50:538-45.
8. Umeda Y, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Saito Y, et al. Dual-time-point (18)F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging. 2009;36:1121-30.
9. Nusair S, Rubinstein R, Freedman NM, Amir G, Bogot NR, Izhar U, et al. Positron emission tomography in interstitial lung disease. Respirology. 2007;12:843-7. (Pubitemid 350064024)
10. Meissner H, Soo-Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73:197-202.
11. Ambrosini V, Zompatori M, De Luca F, Antonia D, Allegri V, Nanni C, et al. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010;51:1950-5.
12. Win T, Screaton NJ, Porter J, Endozo R, Wild D, Kayani I, et al. Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[(18)F]fluoro-d-glucose. Mol Imaging. 2011;Sep 28. Epub ahead of print.
13. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-6. (Pubitemid 47268746)
14. Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary investigation. Eur J Nucl Med Mol Imaging. 2011;38:2238-2246. doi:10.1007/s00259-011-1906-x.
15. Studholme C, Hill DLG, Hawkes DJ. An overlap invariant entropy measure of 2D medical image alignment. Pattern Recogn. 1999;32:71-86.
16. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Resp Crit Care Med. 1994;150:967-72. (Pubitemid 24318021)
17. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844-54.
18. Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690-6.
19. Chaudhari AJ, Bowen SL, Burkett GW, Packard NJ, Godinez F, Joshi AA, et al. High-resolution (18)F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2010;37:1047.
20. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloidbeta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-72.
21. Ishii H, Nishio M, Takahashi H, Aoyama T, Tanaka M, Toriyama T, et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther. 2010;32:2337-47.
22. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369-78.
23. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 suppl 1:122S-50S.
24. Hofman MS, Hicks RJ. Restaging: should we percist without pattern recognition? J Nucl Med. 2010;51:1830-2.
25. Chua S, Dickson J, Groves AM. PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:1591-4
26. de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3′-deoxy-3′- fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging. 2009;36:389-95.
27. de Langen AJ, Lubberink M, Boellaard R, Spreeuwenberg MD, Smit EF, Hoekstra OS, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med. 2008;49:1763-8.
28. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871-8. (Pubitemid 351793426)
29. Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, et al. Assessment of inter-observer reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009;50:1760-9.
30. Robinson PJ, Kreel L. Pulmonary tissue attenuation with computed tomography: comparison of inspiration and expiration scans. J Comput Assist Tomogr. 1979;3:740-8. (Pubitemid 10194605)
31. Verschakelen JA, Van-fraeyenhoven L, Laureys G, Demedts M, Baert AL. Differences in CT density between dependent and nondependent portions of the lung: influence of lung volume. AJR Am J Roentgenol. 1993;161:713-7. (Pubitemid 23296617)
32. Nobuta M, Miyauchi M, Mimura K, Matsuoka A, Sugita M, Kitada O. Influence of body positions on phase IV in a single nitrogen breath method. Rinsho Byori. 1981;29:1062-6.
33. Inoue K, Okada K, Taki Y, Goto R, Kinomura S, Fukuda H. 18FDG uptake associated with CT density on PET/CT in lungs with and without chronic interstitial lung diseases. Ann Nucl Med. 2009;23:277-81.
34. McQuaid SJ, Hutton BF. Sources of attenuation-correction arefacts in cardiac PET/CT and SPECT/CT. Eur J Nucl Med Mol Imaging. 2008;35:1117-23.
35. Dawood M, Lang N, Jiang X, Schafers KP. Lung motion correction on respiratory gated 3-D PET/CT images. IEEE Trans Med Imaging. 2006;25:476-85.